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Abstract
Spinocerebellar ataxia type 2 (SCA2) is the second most frequent autosomal dominant inherited ataxia worldwide. We
investigated the capability of magnetic resonance imaging (MRI) to track in vivo progression of brain atrophy in SCA2 by
examining twice 10 SCA2 patients (mean interval 3.6 years) and 16 age- and gender-matched healthy controls (mean
interval 3.3 years) on the same 1.5 T MRI scanner. We used T1-weighted images and tensor-based morphometry (TBM) to
investigate volume changes and the Inherited Ataxia Clinical Rating Scale to assess the clinical deficit. With respect to
controls, SCA2 patients showed significant higher atrophy rates in the midbrain, including substantia nigra, basis pontis,
middle cerebellar peduncles and posterior medulla corresponding to the gracilis and cuneatus tracts and nuclei, cerebellar
white matter (WM) and cortical gray matter (GM) in the inferior portions of the cerebellar hemisphers. No differences in WM
or GM volume loss were observed in the supratentorial compartment. TBM findings did not correlate with modifications of
the neurological deficit. In conclusion, MRI volumetry using TBM is capable of demonstrating the progression of
pontocerebellar atrophy in SCA2, supporting a possible role of MRI as biomarker in future trials.
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Introduction
Spinocerebellar ataxia type 2 (SCA2) is the second most
frequent autosomal dominant inherited ataxia worldwide after
SCA3 [1,2]. SCA2 is a typical neurodegenerative disease, namely
a progressive and ultimately fatal disorder [3]. Despite active
research [3], neither effective drugs nor the therapeutic window to
slow, halt and hopefully reverse the degenerative process in SCA2
have been established to date. In this context, identification of
reliable and sensitive biomarkers of disease progression, which
could potentially be employed in future trials, is extremely
desirable.
Cross-sectional magnetic resonance imaging (MRI) studies using
T1-weighted images have allowed in vivo detection of brainstem
and cerebellar atrophy in SCA2, as well as the investigation of
possible correlations between volume loss and genetic or clinical
features [4–16]. So far, four longitudinal MRI studies have used
T1-weighted imaging in conjunction with global volumetry or
voxel-based morphometry (VBM) to investigate the progression of
brain atrophy in autosomal dominant inherited ataxias (including
SCA1, SCA3, SCA6 [17,18] and SCA17 [19]) as well as in multi
system atrophy (MSA) [20]. To the best of our knowledge, the
longitudinal progression of atrophy in SCA2 has not yet been
investigated through MRI.
Tensor-based morphometry (TBM) is an advanced approach to
evaluating local volume differences and changes in cross-sectional
and longitudinal studies, respectively. TBM is preferable to VBM
analysis since it does not need to rely on preventive gray matter
(GM) and white matter (WM) segmentation (which can be
particularly cumbersome in the brainstem and cerebellum) [21–
28]. It employs high-dimensional nonlinear deformations to either
register every subject’s anatomy to a custom-built, study-specific
template (cross sectional studies) or to register each subject’s late
T1-weighted image to their early T1-weighted image (longitudinal
studies), after which local volumetric differences or changes are
assessed by computing the voxel-wise Jacobian determinant |J| of
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amount of local volume variation, sometimes referred to as yearly
warp rate (WR), can be calculated. The advantages of TBM in
longitudinal studies have recently been highlighted [24].
In the present study, we used high-resolution T1-weighted MRI
acquisitions of the brain in conjunction with an optimized, ad hoc
implementation of longitudinal TBM in order to track the
progression of local atrophic changes over a mean time span of
3.4 years in 10 patients with SCA2 and 16 age- and gender-
matched healthy controls. Additionally, we investigated possible
correlations between longitudinal rates of volumetric change and
clinical modifications over the same time span.
Materials and Methods
Participants
Ten patients (4 women, 6 men; mean age 47.5612.7 years) with
a genetically confirmed diagnosis of SCA2 [32] gave their written
consent to participating in this longitudinal study. The study was
approved by the Ethic Committee of Careggi University Hospital
of Florence. The cut-off number of triplet repeats expansions
qualifying for diagnosis of SCA2 was 34 CAG on one allele, and
the mean number of abnormal triplets was 40.661.4 (Table 1).
Patients were examined twice using the same 1.5 T MRI
scanner and acquisition protocol, on average 3.660.7 years apart
(range 2.2-4.1). At the time of both MRI examinations, all patients
also underwent evaluation by the same clinician (A.G.) who
assessed disease duration since onset of symptoms and the
neurological deficit using the Inherited Ataxia Clinical Rating
Scale (IACRS) [33]. The IACRS is a 0–38 scale (where 38
corresponds to maximum clinical deficit), originally developed for
Friedreich ataxia, which evaluates signs and symptoms related to
ataxia but also to pyramidal tract dysfunction and impaired
vibration or position sense. Due to this improved capability to rate
the global neurological deficit observed in SCA2 patients (related
to damage of the brainstem, cerebellum, and long motor and
sensitive pathways) the IACRS was preferred to the Scale for the
Assessment and Rating of Ataxia (SARA) which evaluates
cerebellar symptoms and signs [12].
At the time of baseline MRI, the mean disease duration from
clinical onset in SCA2 patients was 12.867.3 years (range 2–23)
and the mean IACRS score was 17.264.3 (range 9–25) (Table 1).
A group of 16 age- and gender-matched healthy subjects (7
women, 9 men; mean age 50.3618.8 years) were recruited as
controls and gave written consent to participating in the study.
They had no history of neurological or psychiatric dysfunction and
their neurological examination was negative. Controls were
examined twice, on average 3.361.0 years apart (range 1.9–4.7),
using the same 1.5 T MRI scanner and acquisition protocol
employed for SCA2 patients. Source T1 weighted images in
patients and controls can be made freely available upon request.
VBM results at baseline examination in 9 of our SCA2 patients
and 10 out of the healthy controls have been previously reported
[8].
MRI examination
All patients and controls underwent examination in a single
centre on a 1.5 T MRI scanner (Philips Intera, Best, The
Netherlands) equipped with 33 mT/m maximum gradient
strength and SENSE 6-channel coil technology. After the scout,
sagittal 3D T1-weighted turbo gradient echo [repetition time
(TR)=8.1 ms, echo time (TE)=3.7 ms, flip angle=8u, inversion
time=764 ms, field of view (FOV)=256 mm6256 mm, matrix
size=2566256, 160 contiguous slices, slice thickness=1 mm]
images were acquired for analysis through TBM.
Data analyses
Preprocessing. T1-weighted images were visually evaluated
by an expert neuroradiologist (M.M.) for potential motion artifacts
before entering further image processing. After this visual quality
check, all images were retained for further processing.
TBM. All registration procedures were based on variations of
the SyN algorithm which, in a comparison of 14 registration
strategies, has been shown to provide the most consistently high
accuracy [34]. We employed the Greedy SyN implementation of
the SyN algorithm included in the ANTs package [35]. All image
registrations were initialized through a 12-degree of freedom
(DOF) affine transform which was followed by a nonlinear
diffeomorphic step, and employed neighborhood cross-correlation
as similarity metric. For improved accuracy with respect to the
default package settings, in the second (nonlinear) registration step
we used four multiresolution levels with a maximum number of
200 iterations per level and smoothing resolutions of 3, 2, 1 and
0 mm per level (from coarsest to finest).
Table 1. Demographic, genetic and clinical data in 10 SCA2 patients.
Patient # Age (years) Gender
Number of triplet repeats
expansions Disease duration (years) IACRS baseline IACRS follow-up
1 60.6 M 38 20 20 23
2 28.4 M 39 2 9 14
3 31.5 M 43 7 16 16
4 46.5 F 41 7 17 21
5 47.4 F 41 10 19 27
6 43.7 M 41 8 15 15
7 67.8 M 41 23 14 18
8 54.5 F 42 23 25 31
9 56.9 M 40 14 20 27
10 37.7 F 40 14 17 21
Mean (SD) 47.5 (12.7) 40.6 (1.4) 12.8 (7.3) 17.2 (4.3) 21.3 (5.7)
F, female; IACRS, Inherited Ataxia Clinical Rating Scale; M, male; SD, standard deviation.
doi:10.1371/journal.pone.0089410.t001
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unbiased, population-specific T1 template, we used baseline T1-
weighted images from all (number of subjects=10) patients and an
equal number of randomly selected controls. The template was
generated using a procedure similar to that described in [36].
Briefly, after N4 bias field correction [37], an initial template was
bootstrapped from all baseline images and coregistrations of
individual brain images were iteratively refined to create a group
average, which is often referred to as an optimal average template.
In particular, the algorithm works within the diffeomorphic space
towards building an average shape and appearance brain by
reducing dependence on the topological idiosyncrasy of any
individual brain. Within the ANTs package, the SyN tool is called
to nonlinearly coregister all brain images to one another in an
iterative manner for subsequent intensity averaging. The proce-
dure is repeated recursively, thereby iteratively refining the co-
registration of the constituent images. Five global iterations were
used to build the final template in this study. Creation of the
custom template required approximately 350 hours of CPU time.
Image registration. All N4-corrected baseline images were
registered to the unbiased template as described above. The voxel-
wise jacobian determinant of the nonlinear component of the
warpfield (|J|baseline) was then computed for each subject. In
particular, when the local volume in N4-corrected image is
greater/less than local volume in the unbiased template image the
|J|baseline values are less/greater than 1, respectively.
Also, every N4-corrected follow-up image was registered (intra-
subject) to the N4-corrected baseline image as described above,
and the voxel-wise jacobian determinant |J|longitudinal of the
nonlinear component of the inverse warpfield (i.e. relative to the
transformation which takes the baseline image into the space of the
follow-up image) was computed (resulting in |J|longitudinal being in
baseline image space). The voxel-wise WR was then computed as
WR=(|J|longitudinal - 1)/t, where t is time (in years) between
baseline and follow-up imaging. In particular, WR values less/
greater than 0 indicate contraction/expansion of local tissue
volume, respectively. Finally, maps of voxel-wise WR were
transformed into custom T1 template space by applying the
transformations computed in the previous step (which take
baseline T1-weighted images into custom T1 template space).
Statistical analyses of atrophy rates. All voxel-wise
statistical analyses were performed within the framework of the
general linear model (GLM) while controlling for age and gender
as nuisance covariates.
We employed non-parametric, permutation-based inference
approach which included full correction for multiple comparisons
over space. In particular, p-values were calculated and corrected
for multiple comparisons using the ‘‘3D’’ parameter setting with
threshold-free cluster enhancement (TFCE), thereby avoiding the
use of an arbitrary amount of spatial smoothing as well as
threshold for the initial cluster-formation, which can affect the
sensitivity of statistical analysis and bias results [38]. For each
comparison, we employed 50000 permutation for increased
accuracy, and corrected p-values smaller than 0.05 were
considered statistically significant. Results of all TFCE analyses
were interpreted separately. The comparisons we performed were
a) patients vs. controls at baseline (between-group cross-sectional
analysis, quantity of interest: |J|baseline), b) follow-up vs. baseline
(within-group longitudinal analysis and group x time interaction,
quantity of interest: WR) and c) within-patient group correlation of
WR with number of abnormal CAG triplets, disease duration and
variations (follow-up-baseline) of the neurological deficit as
assessed with IACRS scale. In a) we tested the effect of group,
in b) we tested the effect of time (in each group) and of group x
time interaction, in c) we tested the hypothesis of a regression slope
being larger or smaller than zero. Resulting p-value maps were
transformed into MNI-152 space by applying an affine, 12-DOF
transformation computed by registering the custom T1 template to
the MNI-152 template. In order to avoid creating false p-values,
nearest neighbor interpolation was employed in this step.
Results
Between-group cross-sectional analysis at baseline showed
significant symmetric atrophic changes in SCA2 patients (with
respect to controls, i.e. the |J|baseline in SCA2 patients were
significantly lower than in controls) in the brainstem, middle
cerebellar peduncels, cerebellar WM and adjacent cortical GM.
No significant differences were found in the supratentorial
compartment (Figure 1, Table S1).
Within-group longitudinal analysis in control subjects showed a
circumscribed atrophy (i.e. WR values were significantly smaller
than 0) of the right frontal mid-orbital gyrus and underlying WM
(Figure S1, Table S2) and a symmetrical enlargement (i.e. WR
values were significantly greater than 0) of the lateral ventricles.
Within-group longitudinal analysis in SCA2 patients (Figure S2,
Table S3) showed, in the supratentorial compartment, volume loss
(i.e. WR values were significantly smaller than 0) of the WM in the
left frontal gyrus, temporal lobe, anterior limb of the internal
capsule, and peritrigonal region, and of the GM in the left
midfrontal gyrus, putamen and pallidus and in the thalamus and
hippocampus, bilaterally. The third and lateral ventricles showed
enlargement (i.e. WR values were significantly greater than 0). In
the infratentorial compartment, diffuse volume loss was present in
the midbrain (left cerebral peduncle, right substantia nigra, red
nucleus and medial lemniscus and central region corresponding to
the decussation of the superior cerebellar peduncles), the entire
basis pontis and the medulla (posterior region corresponding to the
tracts and nuclei gracilis and cuneatus). Atrophy symmetrically
involved the middle cerebellar peduncles and peridentate and
hemispheric cerebellar WM, whereas the superior and inferior
cerebellar peduncels were spared. GM atrophy involved the
cerebellar cortex in the superior vermis and flocculonodular
lobules. The cerebral aqueduct and the fourth ventricle were not
enlarged.
Between-group longitudinal analysis (group x time interaction)
(Figure 2, Table S4) showed that SCA2 patients exhibited
Figure 1. Results of the baseline between group (SCA2 vs.
controls) TBM analysis. Voxel-wise corrected p-value maps (thresh-
old-free cluster enhancement, TFCE), testing the null hypothesis of zero
differences in |J|baseline between SCA2 patients and healthy controls.
Highlighted clusters indicate significantly (p,0.05) more pronounced
mean atrophy in SCA2 patients when compared to healthy controls (i.e.
|J|baseline in SCA2 patients significantly lower than |J|baseline in healthy
controls). All maps are overlayed on population-specific T1 template.
These maps show significant symmetric atrophic changes in SCA2
patients (with respect to controls) in the brainstem, middle cerebellar
peduncels, and cerebellar WM and adjacent cortical GM. No significant
differences are observed in the supratentorial compartment.
doi:10.1371/journal.pone.0089410.g001
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to controls, i.e. WR values in SCA2 patients were significantly
lower than WR values in controls) in the midbrain (substantia
nigra and medial lemniscus, bilaterally, right lateral lemniscus and
central region corresponding to decussation of the superior
cerebellar peduncles), the entire basis pontis, the middle cerebellar
peduncles and posterior medulla corresponding to the in the
gracilis and cuneatus tracts and nuclei. The cerebellum showed
loss of WM in the hemispheric and peridentate region and of the
GM in the cerebellar cortex of the inferior portions of the
cerebellar hemisphers. No volume change was observed in the
supratentorial compartment except for enlargement (i.e. WR
values in SCA2 patients were significantly greater than WR values
in controls) of the cerebral ventricles.
The mean IACRS score changed from 17.2 at baseline to 21.3
at follow-up (23.8% worsening, p=0.005, paired t-test). No
significant correlation between WR and disease duration, number
of abnormal CAG triplets and modification of the neurological
deficit between baseline and follow-up MRI was observed.
Discussion
SCA2 belongs to the group of polyglutamine diseases which
include nine neurodegenerative conditions sharing abnormal
expansion of a CAG triplet in the coding region of the mutated
gene as fundamental pathogenetic mechanism [3]. In particular,
SCA2 involves expansion in excess of 32 CAG repeats in the
disease gene Ataxin-2, which is inherited as an autosomal
dominant tract. The expanded Ataxin-2 mainly targets several
pontine neurons and Purkinje cells in the cerebellum, localizes to
RNA containing stress granules and associates with the endoplas-
mic reticulum/Golgi fraction, which is assumed to play a role in
cytoplasmic RNA-related functions [2,39,40].
Besides cerebellar ataxia, clinical features of SCA2 are variable
and early saccadic slowing, pyramidal tract dysfunction, hypore-
flexia, myoclonus and severe tremor are commonly observed [1].
The rate of clinical progression of SCA2 is higher with increasing
CAG expansion size and decreasing age at onset [2,15,41].
Several recent studies focused on defining appropriate clinical
measurements of progression of the neurological deficit in SCA2
[2,41–43]. However, all clinical scales are operator-dependent and
have limited sensitivity to disease progression [44]. In particular,
based on longitudinal clinical examinations spanning 2.4 years, in
serially examined SCA2 patients it was estimated that a minimum
sample size of 57 was necessary to demonstrate a 50% reduction in
clinical progression using a dedicated neurological scale [43].
Gross neuropathological examination of the brain in SCA2
reveals a pattern of pontocerebellar atrophy combined with
variable loss of bulk of the inferior olives and widening of the sulci
of the frontal lobes [1,45–50]. Decrease in the cerebellum’s weight
correlated with longer disease durations, confirming the neurode-
generative type of disease evolution [46].
Also, the microscopic neuropathological examination of the
central nervous system shows a certain degree of heterogeneity in
SCA2. Neuronal loss is widespread but prominent in the cerebellar
cortex and pontine nuclei, the midbrain, medulla, and motor
cortex. The thalamus, basal ganglia, the remainder of the cerebral
cortex and the Clarke column in the spinal cord are affected late in
the disease course [1,45–51], however the dentate is relatively
spared [46,48,50]. WM damage in SCA2 consists of loss of
myelinated fibers and gliosis affecting the transverse pontine fibres,
central cerebellum and the cerebellar folia, the middle and inferior
cerebellar peduncles, medial lemniscus and trigeminal tracts, the
Figure 2. Results of longitudinal between group (SCA2 vs.
controls) TBM analysis. Left pane: Sample axial views of the
difference in average longitudinal warp rate (DWR) maps between
SCA2 patients and healthy controls, where red indicates local atrophy
and blue indicates local enlargement. Right pane: Voxel-wise corrected
p-value maps (threshold-free cluster enhancement, TFCE), testing the
null hypothesis of zero differences in WR between SCA2 patients and
healthy controls. Highlighted clusters indicate significantly (p,0.05)
more pronounced mean atrophy in SCA2 patients when compared to
healthy controls (i.e. WR in SCA2 patients significantly lower than WR in
control subjects). All maps are overlayed on the population-specific T1
template. SCA2 patients exhibit significant volume loss (higher atrophy
rates with respect to controls) in the midbrain (substantia nigra and
medial lemniscus, bilaterally, right lateral lemniscus and central region
corresponding to decussation of the superior cerebellar peduncles), the
entire basis pontis, the middle cerebellar peduncles and posterior
medulla corresponding to the in the gracilis and cuneatus tracts and
nuclei. The cerebellum shows loss of WM in the hemispheric and
peridentate region and of GM in the cerebellar cortex of the inferior
portions of the cerebellar hemisphers.
doi:10.1371/journal.pone.0089410.g002
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[1,45,46,49,51].
MRI-based studies are able to show loss of bulk of the brainstem
and cerebellum, consistent with a pattern of pontocerebellar
atrophy, which is already visible in presymptomatic and early
symptomatic SCA2 gene carriers [5,13,52]. All VBM studies
confirmed atrophy of the brainstem, middle cerebellar peduncles
and cerebellum in symptomatic SCA2 gene carriers [4,6–8,10]
which, in some studies, was combined with circumscribed atrophy
of the frontal, parietal and temporal cortex, thalamus and frontal
and temporal white matter [4,8,10]. The results of our between-
group TBM analysis at baseline confirms the predominant
pontocerebellar atrophy pattern in SCA2.
Previous cross-sectional studies reported a variable correlation
between GM and WM volume loss and disease duration as well as
severity of the clinical deficit [4,6–9,11,14–16]. In particular, the
absence of such correlations was hypothesized to reflect the
presence of atrophy before the onset of symptoms and a slower
rate of progression of neurodegeneration in SCA2 as compared to
SCA1, SCA3 and SCA17 [11,13,41,43].
In contrast with pathological examinations, MRI allows in vivo,
non-invasive tracking of the progression of structural brain damage
in patients with neurodegenerative disease [31,53,54]. This
capability provides a better understanding of disease physiopathol-
ogy and suggests using MRI as a biomarker in clinical trials.
In a longitudinal VBM study in nine patients with SCA17
examined twice 18 months apart, on one hand progression of GM
atrophy in cerebellar and cerebral motor networks correlated with
deterioration of the motor function, and on the other hand
atrophic changes in frontal, limbic, parietal and cerebellar regions
correlated with severity of psychiatric disturbances [19].
A combined approach using semi-automatic ROI-based
volumetry and VBM in patients with SCA1 (n=37), SCA3
(n=19) and SCA6 (n=7) examined 2 years apart showed that
progression of brain atrophy particularly affected the brainstem
and cerebellum in SCA1, the putamen and pallidum in SCA3, and
the cerebellum as well as the thalamus, putamen, caudate and
pallidum in SCA6 [18]. CAG repeat length correlated with
atrophy progression of the cerebellum and pons in SCA1, whereas
no correlation between the progression of atrophy and of the
clinical deficit was observed.
Finally, VBM failed to demonstrate progression of brain
atrophy after one year in 45 patients with SCA3 as compared to
51 healthy controls [17].
In the present study, we explored longitudinal changes of brain
volume in 10 SCA2 patients and 16 age- and gender-matched
healthy controls. TBM has proven to be a robust, high-throughput
imaging marker in Alzheimer’s disease and mild cognitive
impairment [22,24,25], Parkinson disease [55,56] and Huntington
disease [31], and is particularly well suited for longitudinal studies
[24,31]. To the best of our knowledge, so far TBM has never been
employed to assess atrophy distribution and progression in
inherited or sporadic ataxias.
In our SCA2 patients, between-group longitudinal TBM
analysis showed progression of atrophy of the brainstem, middle
cerebellar peduncles and cerebellum during the follow-up period.
This result indicates that neurodegeneration in SCA2 is associated
with an ongoing pontocerebellar atrophy process. Notably, this
aspect per se is not incompatible with demonstration of brainstem
and cerebellar volume loss already present in presymptomatic
SCA2 gene carriers [13,52], which was tentatively attributed to a
possible developmental (rather than degenerative) component of
SCA2 physiopathology [14].
The same analysis showed additional progressive volume loss in
the midbrain, which partly corresponded to the substantia nigra
and medial lemnisci, and in the medulla, which corresponded to
the gracilis and cuneatus tracts and nuclei. Involvement of the
substantia nigra in SCA2 was consistently reported in neuropath-
ological studies [39] and is in agreement with the common
occurrence of parkinsonism or subclinical nigrostriatal dysfunction
[1,57,58]. In turn, the involvement of cuneatus and gracilis tracts
and nuclei and medial lemnisci is recognized pathologically in
SCA2 [39,51] and in line with clinical symptoms and signs of
somatosensory involvement in SCA2 [51].
We also explored the correlation between the rate of progression
of volume changes and clinical deficit. The lack of correlation
between atrophy rate and clinical deterioration which we observed
in SCA2 is in line with the results obtained in SCA1, SCA3 and
SCA6, albeit difficult to interpret due to our small sample size.
We recognize two main limitations of the present study. First,
we examined a small number of patients. Hence we may have
been unable to reveal minor effects, for instance progressive
atrophy of the supratentorial brain or correlation between
progression of regional atrophy and clinical modifications – such
effects could be detectable in a larger cohort. However, with the
perspective of translating our results to the design of clinical trials
including MRI volumetry in conjunction with TBM as surrogate
biomarker, it is important to have been able to measure
meaningful local volume differences in a relatively small cohort.
Second, we performed a single center study. Implementation of
MRI as biomarker for rare diseases such as SCA2 would greatly
benefit from access to large-scale, multicenter studies.
Conclusion
MRI volumetry using TBM is capable of demonstrating the
progression of pontocerebellar atrophy in SCA2, supporting a
possible role of MRI as biomarker in future trials.
Supporting Information
Figure S1 Results of the longitudinal within group
(controls) TBM analysis. Left pane: Sample axial views of
average warp rate (WR) maps in healthy controls, where red
indicates local atrophy and blue indicates local enlargement. Right
pane: voxel-wise corrected p-value maps (threshold-free cluster
enhancement, TFCE) testing the null hypothesis of zero WR.
Highlighted clusters indicate significant (p,0.05) atrophic changes
(i.e. WR significantly lower than zero). All maps are overlayed on
the population-specific T1 template. Healthy controls show a
circumscribed atrophy of the right frontal mid-orbital gyrus and of
the underlying WM.
(TIF)
Figure S2 Results of the longitudinal within group
(SCA2) TBM analysis. Left pane: Sample axial views of
average warp rate (WR) maps in SCA2 patients, where red
indicates local atrophy and blue indicates local enlargement. Right
pane: voxel-wise corrected p-value maps (threshold-free cluster
enhancement, TFCE) testing the null hypothesis of zero WR.
Highlighted clusters indicate significant (p,0.05) atrophic changes
(i.e. WR significantly lower than zero). All maps are overlayed on
the population-specific T1 template. The supratentorial comparte-
ment shows WM volume loss in the left frontal gyrus, temporal
lobe, anterior limb of the internal capsule, and peritrigonal region,
GM volume loss in the left midfrontal gyrus, putamen and pallidus
and in the thalamus and hippocampus, bilaterally. In the
infratentorial compartment, diffuse volume loss is present in the
Progression of Brain Atrophy in SCA2
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nucleus and medial lemniscus and central region corresponding
to the decussation of the superior cerebellar peduncles), and the
entire basis pontis and medulla (posterior region corresponding to
the tracts and nuclei gracilis and cuneatus). Atrophy symmetrically
involves the middle cerebellar peduncles and peridentate and
hemispheric cerebellar WM. GM atrophy involved the cerebellar
cortex in the superior vermis and flocculonodular lobules.
(TIF)
Table S1 Results of the baseline between group (SCA2
vs. controls) TBM analysis. p-values and MNI coordinates
(Talairach Daemon Labels) of local extrema within clusters of
significantly (p,0.05, threshold-free cluster enhancement, TFCE)
more pronounced mean atrophy in SCA2 patients when
compared to healthy controls (i.e. |J|baseline in SCA2 patients
significantly lower than |J|baseline in healthy controls).
(DOC)
Table S2 Results of the longitudinal within group
(controls) TBM analysis. p-values and MNI coordinates
(Talairach Daemon Labels) of local extrema within clusters of
significantly (p,0.05, threshold-free cluster enhancement, TFCE)
mean atrophy in healthy controls (i.e. Warp Rate (WR)
significantly lower than zero).
(DOC)
Table S3 Results of the longitudinal within group
(SCA2) TBM analysis. p-values and MNI coordinates (Talair-
ach Daemon Labels) of local extrema within clusters of
significantly (p,0.05, threshold-free cluster enhancement, TFCE)
mean atrophy in SCA2 patients (i.e. Warp Rate (WR) significantly
lower than zero).
(DOC)
Table S4 Results of longitudinal between group (SCA2
vs. controls) TBM analysis. p-values and MNI coordinates
(Talairach Daemon Labels) of local extrema within clusters of
significantly (p,0.05, threshold-free cluster enhancement, TFCE)
more pronounced mean atrophy in SCA2 patients when
compared to healthy controls (i.e. Warp Rate (WR) in SCA2
patients significantly lower than Warp Rate (WR) in control
subjects).
(DOC)
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